Cargando…
Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. More...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470538/ https://www.ncbi.nlm.nih.gov/pubmed/37535402 http://dx.doi.org/10.1128/mbio.00902-23 |
_version_ | 1785099700397932544 |
---|---|
author | McNamara, Ryan P. Maron, Jenny S. Boucau, Julie Roy, Vicky Webb, Nicholas E. Bertera, Harry L. Barczak, Amy K. Positives Study Staff, The Franko, Nicholas Logue, Jennifer K. Kemp, Megan Li, Jonathan Z. Zhou, Ling Hsieh, Ching-Lin McLellan, Jason S. Siedner, Mark J. Seaman, Michael S. Lemieux, Jacob E. Chu, Helen Y. Alter, Galit |
author_facet | McNamara, Ryan P. Maron, Jenny S. Boucau, Julie Roy, Vicky Webb, Nicholas E. Bertera, Harry L. Barczak, Amy K. Positives Study Staff, The Franko, Nicholas Logue, Jennifer K. Kemp, Megan Li, Jonathan Z. Zhou, Ling Hsieh, Ching-Lin McLellan, Jason S. Siedner, Mark J. Seaman, Michael S. Lemieux, Jacob E. Chu, Helen Y. Alter, Galit |
author_sort | McNamara, Ryan P. |
collection | PubMed |
description | While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. Moreover, whether anamnestic correlates are conserved across variants of concern (VOC), including the Delta and more distant Omicron VOC, remains unclear. To define the anamnestic correlates of immunity, across VOCs, we deeply profiled the humoral immune response in individuals infected with sequence-confirmed Delta or Omicron VOC after completing the vaccination series. While limited acute N-terminal domain and receptor-binding domain (RBD)-specific immune expansion was observed following breakthrough infection, a significant immunodominant expansion of opsonophagocytic Spike-specific antibody responses focused largely on the conserved S2-domain of SARS-CoV-2 was observed. This S2-specific functional humoral response continued to evolve over 2–3 weeks following Delta or Omicron breakthrough, targeting multiple VOCs and common coronaviruses. Strong responses were observed on the fusion peptide (FP) region and the heptad repeat 1 (HR1) region adjacent to the RBD. Notably, the FP is highly conserved across SARS-related coronaviruses and even non-SARS-related betacoronavirus. Taken together, our results point to a critical role of highly conserved, functional S2-specific responses in the anamnestic antibody response to SARS-CoV-2 infection across VOCs. These humoral responses linked to virus clearance can guide next-generation vaccine-boosting approaches to confer broad protection against future SARS-related coronaviruses. IMPORTANCE: The Spike protein of SARS-CoV-2 is the primary target of antibody-based recognition. Selective pressures, be it the adaption to human-to-human transmission or evasion of previously acquired immunity, have spurred the emergence of variants of the virus such as the Delta and Omicron lineages. Therefore, understanding how antibody responses are expanded in breakthrough cases of previously vaccinated individuals can provide insights into key correlates of protection against current and future variants. Here, we show that vaccinated individuals who had documented COVID-19 breakthrough showed anamnestic antibody expansions targeting the conserved S2 subdomain of Spike, particularly within the fusion peptide region. These S2-directed antibodies were highly leveraged for non-neutralizing, phagocytic functions and were similarly expanded independent of the variant. We propose that through deep profiling of anamnestic antibody responses in breakthrough cases, we can identify antigen targets susceptible to novel monoclonal antibody therapy or vaccination-boosting strategies. |
format | Online Article Text |
id | pubmed-10470538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-104705382023-09-01 Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern McNamara, Ryan P. Maron, Jenny S. Boucau, Julie Roy, Vicky Webb, Nicholas E. Bertera, Harry L. Barczak, Amy K. Positives Study Staff, The Franko, Nicholas Logue, Jennifer K. Kemp, Megan Li, Jonathan Z. Zhou, Ling Hsieh, Ching-Lin McLellan, Jason S. Siedner, Mark J. Seaman, Michael S. Lemieux, Jacob E. Chu, Helen Y. Alter, Galit mBio Research Article While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. Moreover, whether anamnestic correlates are conserved across variants of concern (VOC), including the Delta and more distant Omicron VOC, remains unclear. To define the anamnestic correlates of immunity, across VOCs, we deeply profiled the humoral immune response in individuals infected with sequence-confirmed Delta or Omicron VOC after completing the vaccination series. While limited acute N-terminal domain and receptor-binding domain (RBD)-specific immune expansion was observed following breakthrough infection, a significant immunodominant expansion of opsonophagocytic Spike-specific antibody responses focused largely on the conserved S2-domain of SARS-CoV-2 was observed. This S2-specific functional humoral response continued to evolve over 2–3 weeks following Delta or Omicron breakthrough, targeting multiple VOCs and common coronaviruses. Strong responses were observed on the fusion peptide (FP) region and the heptad repeat 1 (HR1) region adjacent to the RBD. Notably, the FP is highly conserved across SARS-related coronaviruses and even non-SARS-related betacoronavirus. Taken together, our results point to a critical role of highly conserved, functional S2-specific responses in the anamnestic antibody response to SARS-CoV-2 infection across VOCs. These humoral responses linked to virus clearance can guide next-generation vaccine-boosting approaches to confer broad protection against future SARS-related coronaviruses. IMPORTANCE: The Spike protein of SARS-CoV-2 is the primary target of antibody-based recognition. Selective pressures, be it the adaption to human-to-human transmission or evasion of previously acquired immunity, have spurred the emergence of variants of the virus such as the Delta and Omicron lineages. Therefore, understanding how antibody responses are expanded in breakthrough cases of previously vaccinated individuals can provide insights into key correlates of protection against current and future variants. Here, we show that vaccinated individuals who had documented COVID-19 breakthrough showed anamnestic antibody expansions targeting the conserved S2 subdomain of Spike, particularly within the fusion peptide region. These S2-directed antibodies were highly leveraged for non-neutralizing, phagocytic functions and were similarly expanded independent of the variant. We propose that through deep profiling of anamnestic antibody responses in breakthrough cases, we can identify antigen targets susceptible to novel monoclonal antibody therapy or vaccination-boosting strategies. American Society for Microbiology 2023-08-03 /pmc/articles/PMC10470538/ /pubmed/37535402 http://dx.doi.org/10.1128/mbio.00902-23 Text en Copyright © 2023 McNamara et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article McNamara, Ryan P. Maron, Jenny S. Boucau, Julie Roy, Vicky Webb, Nicholas E. Bertera, Harry L. Barczak, Amy K. Positives Study Staff, The Franko, Nicholas Logue, Jennifer K. Kemp, Megan Li, Jonathan Z. Zhou, Ling Hsieh, Ching-Lin McLellan, Jason S. Siedner, Mark J. Seaman, Michael S. Lemieux, Jacob E. Chu, Helen Y. Alter, Galit Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern |
title | Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern |
title_full | Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern |
title_fullStr | Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern |
title_full_unstemmed | Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern |
title_short | Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern |
title_sort | anamnestic humoral correlates of immunity across sars-cov-2 variants of concern |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470538/ https://www.ncbi.nlm.nih.gov/pubmed/37535402 http://dx.doi.org/10.1128/mbio.00902-23 |
work_keys_str_mv | AT mcnamararyanp anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT maronjennys anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT boucaujulie anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT royvicky anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT webbnicholase anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT berteraharryl anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT barczakamyk anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT positivesstudystaffthe anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT frankonicholas anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT loguejenniferk anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT kempmegan anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT lijonathanz anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT zhouling anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT hsiehchinglin anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT mclellanjasons anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT siednermarkj anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT seamanmichaels anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT lemieuxjacobe anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT chuheleny anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern AT altergalit anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern |